Robert Sarrazin

Chief Investment Officer & Managing Partner

Mr. Sarrazin is Chief Investment Officer and Managing Partner of the Autism Impact Fund where he oversees the firm and leads AIF’s Life Sciences practice. Rob’s career as a longtime healthcare investor, private equity partner and corporate development executive includes decades of experience overseeing a large portfolio of control investments, including corporate strategic transactions and over 30+ middle market growth acquisitions under multiple private equity funds.

Most recently, Rob was the VP Global Head of External Innovation and Direct Investments for the GlaxoSmithKline (“GSK”) Consumer Healthcare division, where he built a new strategically focused corporate development capability. Rob managed a global team, reviewed over 7,000 medical innovations and start-ups, and closed 30+ transactions with emphasis on digital devices, AI and diagnostics, neuromodulation, microbiome, Rx to OTC Switch, bio-actives, and category line extensions.

Rob played a critical role in developing several strategic initiatives at GSK focused on transforming the future of self-care, looking to give consumers and patients more control over their healthcare choices.

Prior to working at GSK, Rob was a Senior Partner at CSW, a private equity firm specializing in buyouts, recapitalizations, and growth capital transactions in middle market companies. Before working at CSW, Rob worked for 16 years for the private equity division of Charter Oak Partners, where he focused on middle market control acquisitions across the healthcare, consumer products and industrials sectors.

Rob is a skilled life sciences investor and team builder with experience bringing together corporates, startups, academics, and individual inventors. Rob is dedicated to leveraging his unique background, combining senior operational roles and private equity partner experience, to catalyze change for the autism community.

Rob has a bachelor’s degree in business administration from Richard Ivey Business School (Canada) and an MBA from the Leonard N. Stern School of Business, New York, NY (Valedictorian).